Does Muscle Mass At Intensive Care Unit Admission Determine Mortality: the Memo Study (NCT05834894) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Does Muscle Mass At Intensive Care Unit Admission Determine Mortality: the Memo Study
Switzerland4,000 participantsStarted 2010-01-01
Plain-language summary
This retrospective monocentric study aims to investigate whether a low muscle mass at ICU admission and its loss over the ICU stay predicts mortality, and in what proportion we can counteract it by nutritional support.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Associations of baseline body composition with clinical outcomes:
Adults ≥ 18 yrs, hospitalized in the ICU of the HUG between January 1st 2010 and December 31st 2022 and Abdominal, or thoraco-abdominal CT scan measured 48 hours before to 96 hours after ICU admission in the HUG
* Associations of body composition changes with clinical outcomes, nutritional support or medico-economic paratemers:
Identical as for the associations of baseline body composition with clinical outcomes and At least one additional CT performed during the hospital stay
Exclusion Criteria:
* Associations of baseline body composition with clinical outcomes:
CT scans of low quality or CT scans performed outside of the HUG or Presence of a documented refusal
* Associations of body composition changes with clinical outcomes, nutritional support or medico-economic paratemers:
Additionnally: oral nutrition, because we cannot assess the quantity and composition of oral intakes retrospectively
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
30-day mortality
Timeframe: 30-day mortality between January 1st 2010 and December 31st 2022.